MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish one request received from a shareholder for issue of duplicate share certificate. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q3 FY23 Earnings Conference Call held on February 14, 2023 MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the aforesaid Financial Results Conference Call is hosted on the website of the Company under the following link: http://marksanspharma.com/investors-meet.html Marksans Pharma Results Earnings Call for Q3FY23
Conference Call with Marksans Pharma Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith copies of unaudited financial results of the Company for the quarter ended December 31, 2022 published today i.e February 14, 2023 in the Business Standard (English) and Lakshadeep (Marathi) newspapers. MARKSANS PHARMA LTD. - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDl/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 31st December, 2022 is given in "Annexure A". Q3FY23 Quarterly Result Announced for Marksans Pharma Ltd.
Marksans Pharma announced Q3FY23 results: Q3FY23: Operating revenue was Rs 479.8 crore, up by +32.3% YoY driven by strong volume growth and market share gains in the existing products and markets US business grew by +37.8%. UK and Europe grew by +25.4% Gross profit was Rs 240.3 crore, up by +23.2% YoY with gross margin at 50.1%. EBITDA was Rs 76.6 crore, grew by 32.6% with EBITDA margin at 16.0% EPS grew by 30% YoY to Rs 1.56 9MFY23: Operating revenue at Rs 1,366.2 crore, increased by 27.3% YoY Gross profit at Rs 688.6 crore, grew by +21.3% YoY with gross margin at 50.4% EBITDA at Rs 229.8 crore, increased 17.7% YoY with EBITDA margin at 16.8% Cash balance stood at healthy Rs 417 crore as on 31st December 2022, excluding 75% warrant subscription amount of Rs 279 crore received in January 2023 Free Cash Flow was Rs 145 crore Mark Saldanha, Managing Director of the Company said "We sustained our growth momentum and had another quarter of robust performance across all key geographies. We are confident to continue our trajectory through investment in capabilities. Following OrbiMed’s warrant conversion, Marksans will benefit from their deep global healthcare experience. We remain committed to shareholder value creation and have recently completed the planned buyback. The outlook for the coming years is promising with a strong cash position, increasing the capacities, and wide opportunities in our OTC segment." Result PDF MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated 13th February, 2023 titled Q3FY23 Financial Results MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q3FY23 MARKSANS PHARMA LTD. - 524404 - Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2022 And Limited Review Report Thereon
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and nine months ended 31st December, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 13th February, 2023 along with Limited Review Reports given by statutory auditor of the Company.